---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000160"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:09:38.463513+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025

## Summary
- ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.
- Median duration of response not reached; 13 patients >6 months, 5 >1 year on treatment.
- Well tolerated; only 1 grade 1 atrial fibrillation; common AEs: purpura/contusion, fatigue, petechiae, neutropenia.
- Responses across baseline BTK (38.6%), PLCG2 (12.3%), TP53 (40.4%) mutations and CNS involvement (5 patients).
- Company on track to initiate pivotal trials of NX-5948 in 2025.

## SEC filing metadata
- accession: 0001549595-24-000160
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000160/0001549595-24-000160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000160/nrix-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000160
- JSON: https://secwatch.observer/filing/0001549595-24-000160.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.